Proactive Investors

NanoViricides Files for Rare Pediatric Disease Designation for Measles Drug

NanoViricides announced that it has filed an FDA application for Rare Pediatric Disease designation for its investigational measles antiviral, NV‑387. The move positions the company to qualify for a Priority Review Voucher (PRV) if the drug receives approval, a mechanism that can be sold to other developers for substantial cash. The designation also dovetails with an orphan‑drug filing, promising more frequent FDA interactions and an accelerated review timeline. NanoViricides highlighted the absence of any approved antiviral therapy for measles and cited recent animal‑model success in humanized mice. The company underscored the public‑health gap created by infants too young for vaccination and a CDC‑reported 10% breakthrough rate among fully vaccinated individuals. CEO Dr. Anil Diwan noted that PRVs have fetched as much as $250 million in the past, with recent transactions around $150‑$160 million, providing a potential windfall that could fund commercialization without relying on product sales. He also emphasized the urgency of a therapeutic option given periodic measles spikes in the United States. If approved, NV‑387 could become the first antiviral for measles, offering a treatment for vulnerable pediatric cohorts and generating significant non‑dilutive capital through voucher sales, thereby reshaping the company’s financial outlook and the broader measles‑treatment landscape.